Seagen Inc (NASDAQ:SGEN)
| 212.84 BATS BZX Real-Time Price As of 1:44pm ET |  -3.16 / -1.46%Today’s Change | 116.08 Today|||52-Week Range 217.08 | +65.62% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $40.1B |
Company Description
Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.
Contact Information
Seagen Inc. 21823 30th Drive South East Bothell Washington 98021 |
Employees
Shareholders
| Other institutional | 47.18% |
| Mutual fund holders | 39.74% |
| Individual stakeholders | 25.06% |
Top Executives
| David R. Epstein | Chief Executive Officer & Director |
| Todd E. Simpson | Chief Financial Officer |
| Vaughn B. Himes | Chief Technical Officer |
| Roger D. Dansey | Chief Medical Officer & President-Research |
| Karin A. Tollefson | Senior VP & Head-Global Medical Affairs |
